Shares of Hims & Hers(NYSE: HIMS) fell as much as 8% on Tuesday and closed at their low for the day after news broke that Eli Lilly(NYSE: LLY) lowered the price for a key weight loss drug.
Eli Lilly's shot at Hims & Hers
The big news on Tuesday was an announcement that Eli Lilly will sell the weight loss drug Zepbound through its direct-to-consumer website at a 50% discount to the previous price. A 2.5 milligram single-dose vial will cost $399 for a month's supply, while a 5 milligram dose will be $549 per month.
This is the first name-brand GLP-1 weight loss treatment to be this inexpensive without using the shortage exemption Hims & Hers uses to sell a compounded version of the drugs. Today, investors think that's a threat to a key growth avenue for the company.
Good news for Hims & Hers
As much as the market sees this as bad news, I think it's the opposite. Hims & Hers is just as much a customer acquisition platform and distributor of name-brand products as it is a compounder of treatments under its own brand name. So, the company would likely be happy to offer the Zepbound treatment at this price point.
The GLP-1 Hims & Hers currently makes sells for $199 per month, so it's still significantly cheaper than this offering. And we are only a few months into Hims & Hers even offering a GLP-1, so this won't be a big loss for existing sales, even if some customers move to Eli Lilly's direct site.
The market reacted strongly to this news today, but I don't think it will have much impact on Hims & Hers growth long-term.
Should you invest $1,000 in Hims & Hers Health right now?
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $774,894!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. TheStock Advisorservice has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of August 26, 2024
Travis Hoium has positions in Hims & Hers Health. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
